Renowned audiologist joins Neuromod’s Clinical Advisory Board
Irish medical technology company Neuromod Devices Ltd (Neuromod), which specialises in non-invasive neuromodulation technologies, has announced that Professor Richard S. Tyler will join Neuromod’s Clinical Advisory Board. Professor Tyler founded the annual International Conference on Management of Tinnitus and Hyperacusis more than 26 years ago. He occupies roles as professor in the Department of Otolaryngology, Head and Neck Surgery and in the Department of Speech Pathology and Audiology at the University of Iowa, and also continues to see and treat a large number of US tinnitus patients.
The appointment of Professor Tyler to the Clinical Advisory Board follows a number of other appointments by the company this year, including the appointment of Christopher M. Smith to the Board of Directors in June and the appointment of Professor Hubert Lim as Chief Scientific Officer. Dr Ross O’Neill, CEO of Neuromod, commented on the appointment: “We’re delighted to welcome Professor Tyler to Neuromod’s Clinical Advisory Board. He is a world-renowned audiologist who has advanced our understanding of tinnitus and pioneered research into the development of treatments for tinnitus throughout his illustrious career. As a practising audiologist who continues to see and help a large number of tinnitus patients, Professor Tyler’s insight and guidance will be invaluable as we prepare for the commercial roll out of our ground-breaking, home-use tinnitus treatment device.”
Professor Tyler said: “There are estimates of up to 30 per cent of the population suffering from tinnitus and no one seems to want to help them. Many of these patients cannot sleep at night and take medications for anxiety and depression. I am excited to join Neuromod’s Clinical Advisory Board. Neuromod is working with leading tinnitus scientists and is taking an evidence-based approach to develop treatments for this large unmet clinical need. It has conducted some of the largest and most rigorous clinical trials to date in tinnitus. I am glad to play a part in helping them develop viable treatment options for the millions of patients living with this debilitating condition.”